- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | 1.033 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | XFRA 9F1: AUSSETZUNG/SUSPENSION | 442 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDIAGONAL BIO AB... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 10,080 | -0,59 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,512 | -2,10 % | PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| BIOMERIEUX | 86,20 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,900 | -1,02 % | Bio Green Med Solution, Inc. - 8-K, Current Report | ||
| ANAPTYSBIO | 42,830 | +3,40 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli... ► Artikel lesen | |
| GENUS | 27,000 | -2,17 % | Genus PLC - Admission to Trading | ||
| AKESO | 10,205 | 0,00 % | Akeso, Inc.: First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer | HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical... ► Artikel lesen | |
| MEIRAGTX | 8,400 | +1,82 % | MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors | LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of... ► Artikel lesen | |
| ABIONYX PHARMA | 1,512 | 0,00 % | ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply | CER-001: a distinctive manufacturing challenge to produce a full-length recombinant human apoA-I, a 243-amino-acid protein to form a biomimetic HDL particle A strategic partnership including... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,470 | -0,68 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| MAAT PHARMA | 0,953 | 0,00 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
07.10.2026 / 14:10 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,058 | +0,17 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.